While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, researchers urged. Patients with myelodysplastic syndromes (MDS) may ...

Image courtesy of the U.S. Centers for Disease Control. Over the past 50 years, survival rates for a group of blood cancers known as myelodysplastic syndrome (MDS) have not improved, despite the ...

Orca-T significantly improved cGVHD-free survival compared to allo-HSCT, with a 78% vs 38% rate at one year. The study reported a 94% overall survival rate for Orca-T, with no new safety concerns ...

Personalized treatment strategies are increasingly important in managing lung cancer brain metastases, incorporating targeted therapies and immunotherapies. Stereotactic radiosurgery and whole-brain ...

Rytelo (imetelstat) is a medicine used to treat myelodysplastic syndromes (MDS). MDS is a rare group of disorders that affect your blood cells. Most people who get MDS are 65 years of age or older, ...

Patients with myelodysplastic syndromes (MDS) exhibit diverse disease trajectories necessitating different clinical approaches ranging from watch-and-wait strategies to hematopoietic stem cell ...

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...

Five people living with myelodysplastic syndromes (MDS) or in survivorship talk about their experiences with this serious and commonly misunderstood group of conditions. Myelodysplastic syndromes (MDS ...